Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment

NCT01387555 is registered in ClinicalTrials.gov with Jennerex Biotherapeutics as lead sponsor.

NCT NCT01387555
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01387555 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Randomized Trial of JX-594 (Vaccinia GM-CSF / TK-deactivated Virus) Plus Best Supportive Care Versus Best Supportive Care in Patients With Advanced Hepatocellular Carcinoma Who Have Failed Sorafenib Treatment
Lead sponsor
Jennerex Biotherapeutics
Phase
Phase 2
Overall status
Completed
Start date
October 8, 2011
Completion date
October 1, 2013
Enrollment
129 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

hcc, hepatocellular carcinoma, liver cancer